Afghanistan vs Syria: Access to anti-retroviral drugs, female (%)
Afghanistan
38.0%
in 2024
Syria
41.0%
in 2024
Afghanistan rank
129th
Syria rank
127th
Access to anti-retroviral drugs, female (%) over time
- Afghanistan
- Syria
How they compare
Syria currently reports 41.0% against 38.0% in Afghanistan, a difference of 3.0%.
That makes Syria's figure about 1.1 times Afghanistan's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Syria ahead.
Afghanistan ranks 129th and Syria ranks 127th of 141 countries.
Syria has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Afghanistan | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.1% | 5.4% | 5.3% | Syria |
| 2010s | 17.6% | 26.9% | 9.3% | Syria |
| 2020s | 33.8% | 41.4% | 7.6% | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Afghanistan or Syria?
- Syria, at 41.0% against 38.0% in Afghanistan as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Afghanistan and Syria?
- 3.0%, with Syria ahead.
- How many years of comparable data are there for Afghanistan and Syria?
- 25 years are reported by both, from 2000 to 2024.
- How do Afghanistan and Syria rank globally for access to anti-retroviral drugs, female?
- Afghanistan ranks 129th and Syria ranks 127th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.